Vor Biopharma
46 hedge funds and large institutions have $43.2M invested in Vor Biopharma in 2025 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 9 increasing their positions, 18 reducing their positions, and 14 closing their positions.
300% more call options, than puts
Call options by funds: $28K | Put options by funds: $7K
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
2.03% less ownership
Funds ownership: 4.44% → 2.41% (-2%)
8% less funds holding
Funds holding: 50 → 46 (-4)
29% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 14
36% less capital invested
Capital invested by funds: $67.6M → $43.2M (-$24.5M)
50% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 18
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$323K |
| 2 |
Jane Street
New York
|
+$234K |
| 3 |
Renaissance Technologies
New York
|
+$206K |
| 4 |
OAC
OMERS Administration Corp
Toronto,
Ontario, Canada
|
+$168K |
| 5 |
Barclays
London,
United Kingdom
|
+$107K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
-$707K |
| 2 |
Ensign Peak Advisors
Salt Lake City,
Utah
|
-$366K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$222K |
| 4 |
Morgan Stanley
New York
|
-$149K |
| 5 |
SCM
Sarissa Capital Management
Greenwich,
Connecticut
|
-$132K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
VF
51
Virtu Financial
New York
| – | -$60K | -2,724 | Closed |
|
|
LP
52
LMR Partners
London,
United Kingdom
| – | -$56.7K | -2,556 | Closed |
|
|
PAS
53
Point72 Asia (Singapore)
Singapore
| – | -$31.2K | -1,405 | Closed |
|
54
Two Sigma Advisers
New York
| – | -$30.5K | -1,375 | Closed |
|
|
CSS
55
Cubist Systematic Strategies
Stamford,
Connecticut
| – | -$17.9K | -805 | Closed |
|
|
TSS
56
Two Sigma Securities
New York
| – | -$11.2K | -503 | Closed |
|
|
WS
57
Wedbush Securities
Los Angeles,
California
| – | -$11K | -500 | Closed |
|
|
EBA
58
Eagle Bay Advisors
New York
| – | -$167 | -8 | Closed |
|
|
PD
59
Point72 (DIFC)
Dubai,
United Arab Emirates
| – | -$29 | -1 | Closed |
|
60
Citigroup
New York
| – | -$7 | – | – |
|
|
NS
61
NBC Securities
Birmingham,
Alabama
| – | -$1 | – | – |
|
VOR Hedge Fund Activity: Q1 2025 in Review
46 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Vor Biopharma (VOR) for Q1 2025, worth a combined $43.2M — down 36% from $67.6M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of VOR and 10 opened new positions — a net loss of 4 holders — while 18 trimmed existing stakes and 9 added.
The largest buyer was Susquehanna International Group, adding an estimated $323K. The largest seller was Lynx1 Capital Management, exiting entirely with an estimated $707K sold.
- 46 institutional investors held Vor Biopharma (VOR) as of Q1 2025, down from 50 in Q4 2024.
- Funds reported $43.2M of Vor Biopharma stock for Q1 2025, down 36% quarter-over-quarter.
- 10 funds opened new Vor Biopharma positions in Q1 2025 and 14 closed out, a net change of -4 holders.
- The largest Vor Biopharma buyer in Q1 2025 was Susquehanna International Group, an estimated $323K added.
- The largest Vor Biopharma seller in Q1 2025 was Lynx1 Capital Management, an estimated $707K sold.
Based on aggregated 13F filings for Q1 2025.